Narcolepsy Patients Hope FDA Attention Will Spur Drug Research, Shed Misperceptions
Narcolepsy community will tell FDA about the need for new treatments at a patient-focused drug development initiative meeting; research is under way to replace the chemical in the brain that regulates sleep and wakefulness, which a leading researcher likens to insulin for type 1 diabetes.
You may also be interested in...
FDA’s Amy Abernethy describes how agency’s use of real-world data has evolved in response to COVID-19 and the ‘a-ha’ moment of leveraging different data sources to understand the coronavirus. Takeda R&D President Andrew Plump notes difficulties with platform trials and limitations on data sharing.
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.